AR065794A1 - Pirimidodiazepinas sustituidas - Google Patents
Pirimidodiazepinas sustituidasInfo
- Publication number
- AR065794A1 AR065794A1 ARP080101142A ARP080101142A AR065794A1 AR 065794 A1 AR065794 A1 AR 065794A1 AR P080101142 A ARP080101142 A AR P080101142A AR P080101142 A ARP080101142 A AR P080101142A AR 065794 A1 AR065794 A1 AR 065794A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- hydrogen
- attached
- ring
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Los compuestos son utiles para el tratamiento o control de trastornos de proliferacion celular, en particular los trastornos oncologicos. Estos compuestos y las formulaciones que los contienen pueden ser utiles para el tratamiento o control detumores solidos, por ejemplo, los tumores de mama, de colon, de pulmon o de prostata y otros trastornos oncologicos, por ejemplo los linfomas no de Hodgkin. Reivindicacion 1: Un compuesto de la formula (1) en la que R1 es un miembro elegido entreel grupo formado por las formulas (2) en los que R2 es un miembro elegido entre el grupo formado por alquilo C1-5 de cadena lineal o ramificada, alilo, arilo, bencilo, heteroarilo, vinilo, heterociclilo, cicloalquilo C3-7 opcionalmente sustituidocon uno o más grupos alquilo C1-3 y alcoxi C1-3-alquilo C1-3; R3 y R4 se eligen con independencia entre el grupo formado por hidrogeno y metilo; o R2 y uno de R3 y R4, junto con el carbono y el nitrogeno al que están unidos, forman un anillo decinco miembros; R5 y R6 se eligen con independencia entre el grupo formado por hidrogeno, metilo, etilo, propilo, hidroximetilo, hidroxietilo, ciclopropilo, cloro, fluor, bromo y yodo; o R5 y R6, junto con el carbono al que están unidos, forman unciclopropilo o ciclobutilo; o R4 y R6, junto con los carbonos a los que están unidos, forman un anillo de cinco miembros; o R3 y R5, junto con los carbonos a los que están unidos, forman un anillo de cinco miembros; o R2 y uno de R5 y R6, junto conel carbono y el nitrogeno al que están unidos, forman un anillo de seis miembros; R7 es un miembro elegido entre el grupo formado por hidrogeno y alquilo inferior; Y es un miembro elegido entre el grupo formado por hidroxilo, di-alquil C1-3-amino,un anillo heterocíclico de seis miembros que contiene uno o dos heteroátomos elegidos entre el grupo formado por N y O, y NH-R9; R8 y R11 se eligen con independencia entre el grupo formado por hidrogeno, halogeno, metilo y metoxi; R9 es un miembroelegido entre el grupo formado por hidrogeno, piperidinilo, N-bencil-piperidinilo, N-alquilo C1-4-piperidinilo, arilo, heteroarilo, alquilo C1-4, tetrahidropiranilo, imidazolil-alquilo C1-4, amino y di-alquil C1-3-amino-alquilo C1-4, R10 es unmiembro elegido entre el grupo formado por hidrogeno, hidroxilo y benciloxi; y X es un miembro elegido entre el grupo formado por -C(O)NH- y -NHC(O)-; y las sales farmacéuticamente aceptables del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91935807P | 2007-03-22 | 2007-03-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR065794A1 true AR065794A1 (es) | 2009-07-01 |
Family
ID=39415299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101142A AR065794A1 (es) | 2007-03-22 | 2008-03-19 | Pirimidodiazepinas sustituidas |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US7517873B2 (es) |
| EP (1) | EP2139892B1 (es) |
| JP (1) | JP5087640B2 (es) |
| KR (1) | KR101157848B1 (es) |
| CN (2) | CN101636399B (es) |
| AR (1) | AR065794A1 (es) |
| AT (1) | ATE524472T1 (es) |
| AU (1) | AU2008228303B2 (es) |
| BR (1) | BRPI0809088A2 (es) |
| CA (1) | CA2680757A1 (es) |
| CL (1) | CL2008000785A1 (es) |
| CY (1) | CY1112102T1 (es) |
| DK (1) | DK2139892T3 (es) |
| ES (1) | ES2371832T3 (es) |
| HK (1) | HK1139936A1 (es) |
| HR (1) | HRP20110807T1 (es) |
| IL (1) | IL200617A (es) |
| MX (1) | MX2009010034A (es) |
| PE (1) | PE20120495A1 (es) |
| PL (1) | PL2139892T3 (es) |
| PT (1) | PT2139892E (es) |
| SI (1) | SI2139892T1 (es) |
| TW (1) | TWI363629B (es) |
| WO (1) | WO2008113711A1 (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5380447B2 (ja) * | 2007-08-15 | 2014-01-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | 増殖性疾患の処置のための、ヒトタンパク質キナーゼｐｌｋ１ないしｐｌｋ４の阻害剤としての４−（９−（３，３−ジフルオロシクロペンチル）−５，７，７−トリメチル−６−オキソ−６，７，８，９−テトラヒドロ−５ｈ−ピリミド［４，５−ｂ［１，４］ジアゼパン−２−イルアミノ］−３−メトキシベンザミド誘導体 |
| JP5372939B2 (ja) * | 2007-09-25 | 2013-12-18 | 武田薬品工業株式会社 | ポロ様キナーゼ阻害剤 |
| EP2610256B1 (en) | 2007-09-28 | 2016-04-27 | Cyclacel Limited | Pyrimidine derivatives as protein kinase inhibitors |
| US20090291938A1 (en) * | 2007-11-19 | 2009-11-26 | Takeda Pharmaceutical Company Limited | Polo-like kinase inhibitors |
| TWI490214B (zh) | 2008-05-30 | 2015-07-01 | 艾德克 上野股份有限公司 | 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途 |
| WO2009153197A1 (en) * | 2008-06-18 | 2009-12-23 | F. Hoffmann-La Roche Ag | Halo-substituted pyrimidodiazepines as plkl inhibitors |
| AP2011005745A0 (en) | 2008-12-09 | 2011-06-30 | Gilead Sciences Inc | Modulators of toll-like receptors. |
| WO2010080712A2 (en) | 2009-01-06 | 2010-07-15 | Dana Farber Cancer Institute | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
| SI2442809T1 (sl) | 2009-06-17 | 2017-01-31 | Vertex Pharmaceuticals Incorporated | Inhibitorji replikacije virusov gripe |
| ES2661850T3 (es) | 2009-09-14 | 2018-04-04 | Gilead Sciences, Inc. | Moduladores de receptores del tipo toll |
| WO2012083117A1 (en) | 2010-12-16 | 2012-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| EP3738964A1 (en) | 2013-03-15 | 2020-11-18 | Dana Farber Cancer Institute, Inc. | Pyrimido-diazepinone compounds and methods of treating disorders |
| CA2918910A1 (en) | 2013-07-25 | 2015-01-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcription factors and uses thereof |
| TWI652014B (zh) | 2013-09-13 | 2019-03-01 | 美商艾佛艾姆希公司 | 雜環取代之雙環唑殺蟲劑 |
| AU2014348752C1 (en) | 2013-11-13 | 2019-11-21 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
| MX382171B (es) | 2013-11-13 | 2025-03-13 | Vertex Pharmaceuticals Incorporated | Inhibidores de replicacion del virus de influenza. |
| WO2015117087A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| EP3099677A4 (en) | 2014-01-31 | 2017-07-26 | Dana-Farber Cancer Institute, Inc. | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
| PL3166607T3 (pl) | 2014-07-11 | 2023-02-20 | Gilead Sciences, Inc. | Modulatory receptorów toll-podobnych do leczenia hiv |
| JP2017526741A (ja) | 2014-08-08 | 2017-09-14 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | ジアゼパン誘導体およびその使用 |
| SI3194401T1 (sl) | 2014-09-16 | 2020-12-31 | Gilead Sciences, Inc. | Trdne oblike modulatorja toličnega receptorja |
| PT3194402T (pt) | 2014-09-16 | 2019-02-11 | Gilead Sciences Inc | Métodos de preparação de moduladores dos recetores tipo toll |
| WO2016183116A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
| MA42422A (fr) | 2015-05-13 | 2018-05-23 | Vertex Pharma | Inhibiteurs de la réplication des virus de la grippe |
| US10702527B2 (en) | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| SG10202007099TA (en) | 2015-09-11 | 2020-08-28 | Dana Farber Cancer Inst Inc | Acetamide thienotriazoldiazepines and uses thereof |
| EP3347021A4 (en) | 2015-09-11 | 2019-07-24 | Dana-Farber Cancer Institute, Inc. | CYANO-THIENOTRIAZOLOAZEPINES AND THEIR USES |
| SG11201803210YA (en) | 2015-11-25 | 2018-05-30 | Dana Farber Cancer Inst Inc | Bivalent bromodomain inhibitors and uses thereof |
| EP3440084B1 (en) * | 2016-04-07 | 2022-12-21 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone kinase scaffold compounds and methods of treating pi3k-mediated disorders |
| AU2020356484A1 (en) * | 2019-09-27 | 2022-03-17 | Dana-Farber Cancer Institute, Inc. | ERK5 degraders as therapeutics in cancer and inflammatory diseases |
| KR102313753B1 (ko) * | 2020-03-27 | 2021-10-19 | (주) 업테라 | Plk1의 선택적 분해를 유도하는 바닐린 유도체 화합물 |
| WO2022145989A1 (ko) * | 2020-12-31 | 2022-07-07 | (주) 업테라 | 선택적 plk1 억제제로서의 피리미도디아제핀 유도체 |
| KR102604801B1 (ko) | 2021-08-10 | 2023-11-22 | (주) 업테라 | 신규 plk1 분해 유도 화합물 |
| GB202313514D0 (en) | 2023-09-05 | 2023-10-18 | Cambridge Entpr Ltd | Treatment of inflammatory diseases |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0014075A (pt) * | 1999-09-17 | 2002-07-16 | Abbott Gmbh & Co Kg | Inibidores de quinase como agentes terapêuticos |
| JP3876254B2 (ja) | 2001-09-04 | 2007-01-31 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 新規なジヒドロプテリジノン、その製造方法及びその医薬組成物としての使用 |
| WO2007095188A2 (en) * | 2006-02-14 | 2007-08-23 | Vertex Pharmaceuticals Incorporated | Dihydrodiazepines useful as inhibitors of protein kinases |
| TW200808325A (en) * | 2006-07-06 | 2008-02-16 | Astrazeneca Ab | Novel compounds |
-
2008
- 2008-03-11 CN CN2008800088890A patent/CN101636399B/zh not_active Expired - Fee Related
- 2008-03-11 CA CA002680757A patent/CA2680757A1/en not_active Abandoned
- 2008-03-11 PL PL08717594T patent/PL2139892T3/pl unknown
- 2008-03-11 DK DK08717594.9T patent/DK2139892T3/da active
- 2008-03-11 EP EP08717594A patent/EP2139892B1/en not_active Not-in-force
- 2008-03-11 MX MX2009010034A patent/MX2009010034A/es active IP Right Grant
- 2008-03-11 KR KR1020097019761A patent/KR101157848B1/ko not_active IP Right Cessation
- 2008-03-11 ES ES08717594T patent/ES2371832T3/es active Active
- 2008-03-11 CN CN201210030872.3A patent/CN102746175B/zh not_active Expired - Fee Related
- 2008-03-11 BR BRPI0809088-2A patent/BRPI0809088A2/pt not_active IP Right Cessation
- 2008-03-11 SI SI200830445T patent/SI2139892T1/sl unknown
- 2008-03-11 PT PT08717594T patent/PT2139892E/pt unknown
- 2008-03-11 WO PCT/EP2008/052847 patent/WO2008113711A1/en active Search and Examination
- 2008-03-11 JP JP2009553997A patent/JP5087640B2/ja not_active Expired - Fee Related
- 2008-03-11 AT AT08717594T patent/ATE524472T1/de active
- 2008-03-11 AU AU2008228303A patent/AU2008228303B2/en not_active Ceased
- 2008-03-18 CL CL2008000785A patent/CL2008000785A1/es unknown
- 2008-03-19 TW TW097109660A patent/TWI363629B/zh not_active IP Right Cessation
- 2008-03-19 US US12/051,000 patent/US7517873B2/en not_active Expired - Fee Related
- 2008-03-19 PE PE2011001933A patent/PE20120495A1/es not_active Application Discontinuation
- 2008-03-19 AR ARP080101142A patent/AR065794A1/es unknown
-
2009
- 2009-08-27 IL IL200617A patent/IL200617A/en not_active IP Right Cessation
-
2010
- 2010-07-05 HK HK10106507.1A patent/HK1139936A1/xx not_active IP Right Cessation
-
2011
- 2011-11-02 HR HR20110807T patent/HRP20110807T1/hr unknown
- 2011-11-30 CY CY20111101174T patent/CY1112102T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20120495A1 (es) | 2012-05-12 |
| AU2008228303A1 (en) | 2008-09-25 |
| DK2139892T3 (da) | 2011-12-12 |
| US7517873B2 (en) | 2009-04-14 |
| ES2371832T3 (es) | 2012-01-10 |
| KR20090119913A (ko) | 2009-11-20 |
| EP2139892A1 (en) | 2010-01-06 |
| US20080234255A1 (en) | 2008-09-25 |
| JP2010521514A (ja) | 2010-06-24 |
| HK1139936A1 (en) | 2010-09-30 |
| CA2680757A1 (en) | 2008-09-25 |
| PL2139892T3 (pl) | 2012-03-30 |
| KR101157848B1 (ko) | 2012-07-11 |
| IL200617A0 (en) | 2010-05-17 |
| PT2139892E (pt) | 2011-11-21 |
| MX2009010034A (es) | 2009-10-12 |
| CL2008000785A1 (es) | 2009-03-27 |
| TWI363629B (en) | 2012-05-11 |
| AU2008228303B2 (en) | 2012-04-19 |
| CY1112102T1 (el) | 2015-11-04 |
| ATE524472T1 (de) | 2011-09-15 |
| HRP20110807T1 (hr) | 2011-12-31 |
| SI2139892T1 (sl) | 2011-12-30 |
| CN102746175A (zh) | 2012-10-24 |
| EP2139892B1 (en) | 2011-09-14 |
| CN101636399B (zh) | 2012-04-18 |
| IL200617A (en) | 2014-02-27 |
| CN102746175B (zh) | 2014-01-15 |
| CN101636399A (zh) | 2010-01-27 |
| WO2008113711A1 (en) | 2008-09-25 |
| TW200843781A (en) | 2008-11-16 |
| BRPI0809088A2 (pt) | 2014-09-09 |
| JP5087640B2 (ja) | 2012-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR065794A1 (es) | Pirimidodiazepinas sustituidas | |
| PE20070490A1 (es) | Compuestos derivados de bencimidazol-2-ona sustituidos con piperidina como agonistas del receptor muscarinico m1 | |
| ES2624795T3 (es) | Derivados de N-(heteroaril)-1-heteroaril-1H-indol-2-carboxamidas, su preparación y su aplicación en terapéutica | |
| ES2521596T3 (es) | Combinación del compuesto GlyT1 con antipsicóticos | |
| AR069480A1 (es) | Derivados de 2-amino-pirimidina | |
| CO5680412A2 (es) | Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino | |
| PE20110329A1 (es) | Agonistas del receptor acoplado a la proteina g piperidinilo | |
| PE20071009A1 (es) | Compuestos derivados de fenoxipiperidinas como antagonistas de histamina h3 | |
| AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| PE20100087A1 (es) | Compuestos y composiciones como inhibidores de cinasa | |
| PE20121358A1 (es) | Derivados de indol como inhibidores itk | |
| PE20070112A1 (es) | Mimeticos de glucocorticoides, metodos para su fabricacion, composiciones farmaceuticas y usos de los mismos | |
| PE20090159A1 (es) | COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs | |
| PE20090952A1 (es) | Compuestos de pirazol moduladores de raf | |
| PE20061298A1 (es) | Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c | |
| PE20161405A1 (es) | Analogos de cortistatina y sintesis y usos de los mismos | |
| AR059328A1 (es) | Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp | |
| PE20080275A1 (es) | Derivados de 5h-benzo[4,5]ciclohepta[1,2]piridina como inhibidores de tirosina quinasa | |
| PE20090372A1 (es) | Derivados de indolinonas como inhibidores de quinasas especificas del ciclo celular | |
| AR045859A1 (es) | Derivados de dibenzoazepina y de benzodiazepinas sustitudos, procesos de preparacion y usos | |
| PE20060937A1 (es) | Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2) | |
| CO6260069A2 (es) | Tiazolopiridin-2-iloxi-fenil y tiazolopirazin-2-iloxi-fenil aminas como moduladores de la leucotrieno a4 hidrolasa | |
| ECSP13012990A (es) | Derivados de pirazolidin-3-ona | |
| AR086024A1 (es) | Derivados de 5-(fenil/piridinil-etinil)-2-piridina/2-pirimidina carboxamidas | |
| MX337443B (es) | Derivados de etinilo como moduladores alostericos positivos del receptor de glutamato metabotropico del subtipo 5 (mglur5). |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |